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these were not taken into account in the search conducted by
Vonberg and Gastmeier. Third and ﬁnally, an editorial written
by Trépanier and Lessard5 in 2003 interestingly afﬁrmed that
5 deaths caused by contaminated propofol were reported during
this time period (>4, as asserted by Vonberg and Gastemeier1
and by Mattner and Gastmeier4).6 Table 1 of this letter presents
the appropriate distribution of the outbreaks caused by
contaminated propofol reported between 1990 and 2005.
In summary, limitations of the inclusion criteria were
likely caused by natural methodological issues concerning the
bibliographic source used by Vonberg by Gastemeier. Given
the restrictions and gaps in the results of their review, we
suggest a traditional systematic search of major bibliographic
databases (eg, PubMed/Medline, EMBASE, Lilacs, and others).6
With a more robust data search, a more complete review could
be conducted. Actually, the contamination of propofol is a
worldwide problem that has been a focus of manufacturers,
who have made pharmacological reforms such as addition
of preservatives and/or modiﬁcation of physical properties
(ie, lipophilic solubility). The issue of determining the overall
mortality related to the contamination of medical drugs is
important, but the results of this particular review need to be
discussed in depth to avoid the reporting of false rates.
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Potential Risk of Aerosol-Borne Francisella
tularensis Transmission in the Operating Room
To the Editor—Tularemia, a potentially life-threatening zoo-
nosis, is caused by the Gram-negative bacterium Francisella
tularensis that occurs naturally in the Northern Hemisphere.1
At least 6 distinct clinical syndromes have been described, and
ulceroglandular tularemia is the most frequent disease mani-
festation in North America and Central Europe.2 Recently,
outbreaks in the United States, Turkey, and some European
countries have led to the recognition of tularemia as an
emerging infectious disease.3 F. tularensis is a highly infectious
agent; a quantity of just 10–25 bacteria can infect a human and
cause severe clinical disease. Hence, F. tularensis is considered a
‘category A’ bioterrorism agent. Transmission may occur
through inhalation of infectious aerosols, direct contact
with infected animals (eg, rodents), arthropod bites, or oral
ingestion of contaminated tissues or water.1 Similar to other
bacterial zoonotic pathogens like Bacillus anthracis and
Brucella melitensis, the causative agents of anthrax and brucellosis,
respectively, person-to-person transmission of tularemia does
generally not occur and infected patients do not need to be
isolated. However, biological specimens from patients with
tularemia may constitute a signiﬁcant threat to healthcare
workers. Indeed, F. tularensis ranks among the 5 most
frequently reported laboratory-acquired infections, and inha-
lation of infectious aerosols is considered a major transmission
route in these cases.4 After a recent case of ulceroglandular
tularemia at our hospital, we investigated the possibility of
tularemia as an airborne healthcare-associated infection in the
operating room.
A 48-year-old male patient presented with painless cervical
swelling on the right side accompanied by occasional fever and
night sweats during the preceding 2 months. The patient
worked as a falconer and reported having frequent contact
with raptors and other wild animals. On clinical examination,
cervical lymphadenopathy was noted. Ultrasound examination
and subsequent magnetic resonance imaging (MRI) showed
multiple enlarged, partially necrotic lymph nodes. Infectious
and neoplastic etiologies were considered, and 1 enlarged
lymph node was surgically removed. Histopathology showed a
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phlegmonous and abscess-forming inﬂammation with no
signs of malignancy. Culture and polymerase chain reaction
(PCR) assays for bacteria, mycobacteria, and fungi were
negative. The patient’s symptoms worsened despite antibiotic
treatment with cefuroxime. A second surgical lymph node
excision was performed 4 weeks later, showing a necrotizing
granulomatous inﬂammation with epithelioid cell granulomas.
Bacterial cultures were negative, but PCR revealed F. tularensis
as the causative agent. The serology report revealed a
markedly increased titer of F. tularensis-speciﬁc IgM, thus
conﬁrming the diagnosis. Antibiotic treatment with doxycy-
cline (200 mg/day for 3 weeks) was started and led to a
rapid decrease of lymphadenitis and resolution of all clinical
symptoms. After the diagnosis had been established, one of the
surgeons reported to the infection prevention team that he
had had painful, unilateral tonsillitis some days after the ﬁrst
surgery. Concerns arose regarding whether the anesthesio-
logist, the surgeons, and the nurses involved in the 2 surgical
procedures might have been at risk of acquiring tularemia
through infectious aerosols. Overall, 5 healthcare workers who
had close contact with the infected tissue specimens were
serologically screened for tularemia 21 days after exposure, but
all tested negative.
The tularemia guidelines issued by the World Health
Organization (WHO) recommend monitoring the body
temperature of an incidentally exposed individual for 14 days
after the event and initiating post-exposure prophylaxis with
ciproﬂoxacin or doxycycline in case of fever or any arising
clinical symptoms.5 In the case presented here, however, none
of the exposed individuals reported an acute feverish illness,
and all tested negative on serology 3 weeks after exposure,
thus excluding tularemia.6 To minimize the risk of healthcare-
associated infections, WHO recommends that clinicians
report any suspicion of tularemia to the diagnostic laboratory.
However, even in endemic areas, tularemia is rarely taken into
account by clinicians, resulting in a low notiﬁcation rate to the
laboratory. Human infections with F. tularensis had never
before been reported from the federal state of Germany where
the patient lives (Saarland); thus, tularemia was not initially
considered in the differential diagnosis.
Human-to-human transmission of tularemia has never
been unambiguously documented, but a literature review
concluded that aerosolized F. tularensis bacteria remain viable
for prolonged time periods and may be inhaled by others.7
Various factors need to be taken into consideration to predict
the risk of infection via aerosols, ie, the actual number of viable
bacterial cells within a handled specimen, the size of droplets
arising from the aerosol, and the intensity of an individual’s
exposure.8 While tularemia is commonly acquired via inhala-
tion by hunters when handling infected animals, it remains to
be elucidated whether this transmission route may also occur
during exposure to infected human specimens. The pathogen
load in human lymph nodes is probably much lower than in
organs from infected rodents, and F. tularensis is mainly
located inside macrophages, which might decrease the
potential infectivity of human specimens. Yet, given the very
low infectious dose of F. tularensis, it may be speculated that
aerosols generated during surgical procedures on bacteria-
containing specimens in the operating room constitute a sig-
niﬁcant risk of infection for the medical staff who are directly
involved. For brucellosis, this exceptional route of transmis-
sion has recently been conﬁrmed.9
We conclude that there is a need for an increased awareness
of the various transmission routes of F. tularensis and the
potentially arising implications for infection control and pre-
vention in hospital settings. Further research is warranted to
accurately assess the signiﬁcance of aerosols as vectors of
infectious diseases in the operating room.
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Port-Related Nontyphoidal Salmonella
Bacteremia
To the Editor—Salmonella species, a genus of the family
Enterobacteriaceae, includes Salmonella enterica serovar Typhi
and nontyphoidal Salmonella (NTS) spp.1,2 Human infections
caused by NTS are often associated with contaminated food
products and always develop in an immunocompromised
host.3 The clinical presentations of NTS infection include
gastroenteritis, primary bacteremia, mycotic aneurysm, infec-
tive endocarditis, urinary tract infection, meningitis, empyema
thoracis, and osteomyelitis.3–7 We performed a study to identify
cases of unusual presentation of NTS infection related to sub-
cutaneously implanted port reservoir and to further investigate
their associated clinical and microbiological characteristics.
This study was conducted at 1 institution, a 900-bed hospital
in southern Taiwan. From the computerized database of the
bacteriology laboratory, we identiﬁed patients whose cultures
yielded NTS. The medical records of all patients with port-
related infection caused by NTS included in this study were
retrospectively reviewed.
The diagnosis of port-related NTS bacteremia was deﬁned
as a primary laboratory-conﬁrmed NTS bacteremia in a
patient with a port at the time of (or within 48 hours prior to)
the onset of symptoms in whom the infection was not related
to another site. Standard deﬁnitions for healthcare-associated
bacteremia (HAIs) were used.8 Inappropriate use of antibiotics
was deﬁned as use of antimicrobial agents to which the clinical
isolates were resistant in vitro.
During the study period, 4 patients were identiﬁed to have
port-related NTS bacteremia: 3 infections were caused by group
D Salmonella, and 1 was caused by group C Salmonella. All of
the clinical isolates were susceptible to ampicillin, ceftazidime,
ceftriaxone, ciproﬂoxacin, trimethoprim-sulfamethoxazole, and
chloramphenicol. The clinical characteristics of 4 patients with
port-related NTS bacteremia are summarized in Table 1. Of
these 4 patients, 3 were men, and the age range of this cohort
was 44–80 years. All of these patients had various cancers, and
1 patient had received chemotherapy prior to NTS infection. All
of these patients had initial presentations of fever; however,
none had signs or symptoms of enteritis. In addition, 1 patient
had diabetes mellitus. Of these 4 patients, 3 had white blood cell
counts >11,000/mm3, and none had neutropenia. In addition,
3 patients had hemoglobin <10 g/dl, and 2 patients had elevated
C-reactive protein levels. None of these patients had their port
removed. Although all 4 patients received appropriate anti-
biotics initially, 1 patient died due to NTS sepsis.
This study describes a rare cluster of NTS bacteremia in
hospitalized cancer patients with ports at a single center. The
immunocompromised conditions among these patients
should be included as major risk factors for NTS bacteremia.
Moreover, all of cases in this survey were classiﬁed as health-
care-associated, catheter-related bloodstream infections.
Although rare, NTS should be considered as a possible
pathogen causing intravascular catheter-related bacteremia in
cancer patients in healthcare settings.
The clinical outcomes of patients with catheter-associated
NTS bacteremia have not been well deﬁned because of the
table 1. Clinical Manifestations of 4 Patients with Nontyphoidal Salmonella Port-Related Infections
Case (year) Age, y Sex Underlying disease
Healthcare-
Associated
Infection Serogroup Neutropenia
Removal of
Catheter Antibiotic Mortality
1 (2008) 62 M Lung cancer
undergoing chemotherapy,
hypertension
Yes D No No Ceftazidime No
2 (2010) 53 M Esophageal cancer,
chronic hepatitis B
Yes D No No Ceftazidime No
3 (2010) 44 M Oral cancer Yes D No No Ceftazidime Yes
4 (2011) 80 F Rectal cancer, ovarian
cancer, diabetes mellitus,
hypertension
Yes C No No Ciproﬂoxacin No
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